A significant correlation between FOXP3 knockdown in the tumor and in the blood at cycle 2, day 1, was observed for patients with a paired biopsy sample (R = 0.63; P < 0.05; Fig. 4B), supporting on-target ASO activity in both the tumor and periphery. The gene discussed is FOXP3; the disease is neoplasm.